Jci_page_head_homepage_01 Jci_page_head_homepage_02
Celia F. Brosnan, Gareth R. John
Published in Volume 119, Issue 1
J Clin Invest. 2009; 119(1):10–13 doi:10.1172/JCI37786
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 1
Notch1 ligands differentially regulate OPC development.

The figure depicts the outcome of the interaction of different ligands with the Notch1 receptor, which triggers signaling via two distinct pathways. Canonical ligands of the DSL family activate genes such as HES1 and HES5 (HES1,5) that inhibit OPC differentiation but permit OPC proliferation, resulting in the maintenance and/or expansion of the OPC pool. In contrast, the noncanonical ligand F3/Contactin leads to OPC differentiation and subsequent myelination of axons by promoting expression of myelin genes such as myelin-associated glycoprotein (MAG). However, in this issue of the JCI, Nakahara et al. (8) present data supporting the conclusion that in MS lesions, activation of the noncanonical pathway may fail due to pathologic upregulation of TIP30, a protein that blocks nuclear transport of NICD. NICD entrapment in the cytoplasm prevents OPC differentiation and axon myelination (see schematic representation depicted in Figure 9 of the Nakahara et al. study; ref. 8).